Three Successful Completed Clinical Trials
Positive Clinical Study for Ingredient and Product Efficacy
Advanced Blood Glucose Management Supplement coming soon to Market.
Positive Clinical Study for Ingredient and Product Efficacy
Study evaluated the safety and efficacy of Diabetinol, a proprietary ingredient, in both an in vivo and a human clinical study.
The results of the in vivo study demonstrated that Diabetinol did not produce any adverse effects in a fructose-induced animal model and showed improvement in blood glucose, insulin, cholesterol and triglycerides.
Human Trial Clinical Study Completed
Advanced Blood Glucose Management Supplement coming soon to Market.
Positive Clinical Study for Ingredient and Product Efficacy
In a human clinical study conducted it was demonstrated that the use of Diabetinol over a three-month period, was safe and effective in significantly reducing glucose intolerance in subjects with impaired fasting glucose (IFG), who were also taking oral medication.
Diabetinol significantly reduced total cholesterol and LDL cholesterol. D
In a human clinical study conducted it was demonstrated that the use of Diabetinol over a three-month period, was safe and effective in significantly reducing glucose intolerance in subjects with impaired fasting glucose (IFG), who were also taking oral medication.
Diabetinol significantly reduced total cholesterol and LDL cholesterol. Decreasing trends in HbA1c were also observed.
The data suggest that Diabetinol as a natural food product may have protective effects in individuals with a combined IFG and hyperlipidemia.
Human Trial Clinical Study Completed
Advanced Blood Glucose Management Supplement coming soon to Market.
Advanced Blood Glucose Management Supplement coming soon to Market.
In the Diabetinol®
group versus the placebo group. Patients achieved the
American Association of Clinical Endocrinologists and American Diabetes Association targets for hemoglobin A
1c, low-density lipoprotein, total cholesterol, and systolic blood pressure.
The clinical study suggests a role for Diabetinol(®) as an adjunctive therap
In the Diabetinol®
group versus the placebo group. Patients achieved the
American Association of Clinical Endocrinologists and American Diabetes Association targets for hemoglobin A
1c, low-density lipoprotein, total cholesterol, and systolic blood pressure.
The clinical study suggests a role for Diabetinol(®) as an adjunctive therapy for glycemic maintenance and for decreasing the risk of diabetes-associated comorbidities in type 2 diabetic patients.
Advanced Blood Glucose Management Supplement coming soon to Market.
Advanced Blood Glucose Management Supplement coming soon to Market.
Advanced Blood Glucose Management Supplement coming soon to Market.
Vegan, all natural blood sugar lowering daily supplement coming to market soon.